Antibody, Bioinformatics, Development and Protein

Absci and M2GEN partner to expedite cancer drug development

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development

Development Bioinformatics Drugs Immune Response

Drug discovery deals highlight key growth areas

Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Olink specialises in solutions for proteomics discovery and development.

Drugs

Drugs Antibody DNA Gene Therapy

Looking ahead to AACR

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein

Protein Clinical Trials Clinical Trials Antibody

Big data – charting a new path to drug discovery and development

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Big Data

Big Data Development Life Science Drugs

Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s

pharmaphorum

OCTOBER 20, 2021

A software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in their earliest stages is being tested in a five-year trial involving thousands of patients.

Trials

Trials Genome Genomics Bioinformatics

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

JULY 27, 2021

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. executive vice president of Research and Development at Amgen. billion in cash.

Production

Production Antibody Sales Manufacturing

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein

Protein Antibody Engineer Scientist

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody

Antibody Engineer Protein Scientist

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer

Engineer Antibody Protein In-Vivo

Reflecting on PEGS Europe 2023

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows.

Antibody

Antibody Protein Engineer In-Vivo

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

NOVEMBER 15, 2022

Known for its ability to offer precision and flexibility while expanding the experimental scale, synthetic biology tools can reduce development timelines and costs, and lend a competitive advantage over traditional methods. . Synthetic libraries for antibody drug discovery . Rapid and accurate DNA synthesis .

DNA

DNA Drugs Antibody Engineer

Exscientia extends capabilities beyond small molecules

Drug Discovery World

NOVEMBER 4, 2022

Throughout 2022, Exscientia has progressed AI-driven capabilities for virtual biologics design, such as human antibodies, and is now establishing an automated biologics laboratory in Oxford to internally generate and profile novel antibodies. . The binding site of the antibody consists of two chains (heavy and light).

Antibody

Antibody Bioinformatics Engineer Protein

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

The Pharma Data

SEPTEMBER 1, 2020

head of Immunology and Fibrosis Development, Bristol Myers Squibb. Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program. Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Author: Minton. Author: Harris.

Trials

Trials Clinical Trials Clinical Trials Vaccination

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

NOVEMBER 7, 2022

Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. In addition, Dr. Bahassi stressed that the simple enumeration of CTCs will not contribute significantly to the development of improved or more personalized cancer treatments. percent show less reliability).

Clinical Trials

Clinical Trials Clinical Trials Trials FDA Approval

How big data analytics can make personalised care a reality

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. Figure 2: Advanced data visualisation examples for transcriptomics data.

Big Data

Big Data RNA Bioinformatics Vaccination

AI in R&D: From hot topic to practical application

Drug Discovery World

SEPTEMBER 7, 2022

By Ashoka Rajendra , Head of Development & Manufacturing Products at Benchling. From discovery, to lead optimsation, process development, pre-clinical, and even investigational new drug filings, each stage of R&D stands to benefit from AI. . The solution is software, but it’s not that simple .

Scientist

Scientist Life Science Antibody Protein

Big pharma companies partner to form AI-based start-up

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . The partners want to focus on riskier, more complex structures of proteins to try to decipher them.

Pharma Companies

Pharma Companies Antibody Protein Development

What to expect from SLAS Europe 2023

Drug Discovery World

APRIL 21, 2023

Atrandi Biosciences’ novel technology platform enables researchers to gain insights into the biology of single cells, offering immediate applications in single-cell sequencing, drug and antibody discovery, functional metagenomics, microbial analysis, directed evolution, and synthetic biology. It will be led by Björn C.

Doctors

Doctors Doctor Genetics In-Vitro

Clinical Research Informer

Absci and M2GEN partner to expedite cancer drug development

Drug discovery deals highlight key growth areas

Trending Sources

Looking ahead to AACR

Big data – charting a new path to drug discovery and development

Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

What to expect from PEGS Europe 2023: Day 3

What to expect from PEGS Europe 2023: Day 1

What to expect from PEGS Europe 2023: Day 2

Reflecting on PEGS Europe 2023

Synthetic biology tools advancing and accelerating drug discovery efforts

Exscientia extends capabilities beyond small molecules

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

The Utility of Liquid Biopsy in Oncology Clinical Trials

How big data analytics can make personalised care a reality

AI in R&D: From hot topic to practical application

Big pharma companies partner to form AI-based start-up

What to expect from SLAS Europe 2023

Stay Connected